|
|
| VGX
Pharmaceuticals Announces Promotion of Niranjan Y. Sardesai,Ph.D.,
to Vice President of Product Development
|
| Blue
Bell, PA – January 2, 2007– |
|
VGX Pharmaceuticals today announced the promotion of
Niranjan Y. Sardesai, Ph.D., to Vice President of Product Development.
Dr. Sardesai has been serving as the Senior Director of Product Development.
Since joining VGX in 2006, Dr. Sardesai has been a member of the senior
management team overseeing VGX’s pre-clinical activities and managing
strategic planning and development alliances across industry and academia.
“Niranjan has provided VGX with critical strategic and technical
leadership in meeting our development milestones,” said Dr. Joseph
Kim, CEO and President. “With his strong credentials and knowledge
of our company, we look forward to Niranjan taking on a greater role in
executing our strategic plan for transforming VGX into a leading global
biopharmaceuticals company,” added Dr. Kim. “As a member of
our executive management team, he will continue to contribute in his exceptional
strategic capacity as well as assuming the additional operational role
of guiding VGX’s growth through identifying and managing acquisition
transactions.”
Dr. Sardesai is an experienced veteran of the biotechnology industry,
with a special focus in R&D and Management of Technology. Prior to
joining VGX, Dr. Sardesai was the President of Nvision Consulting, Inc.
He also served as the Director of R&D and Director of Applied Research
at Fujirebio Diagnostics, Inc. At Fujirebio, Dr. Sardesai oversaw all
aspects of the company’s R&D activities, with a special focus
on new product development. Prior to Fujirebio, he worked as a Senior
Scientist at IGEN International, Inc.
Dr. Sardesai received a Ph.D. in Chemistry from California Institute of
Technology and an MBA in Entrepreneurial Management from the Wharton School
of the University of Pennsylvania. Dr. Sardesai also completed post-doctoral
fellowships at the Scripps Research Institute and the Massachusetts Institute
of Technology. Dr. Sardesai graduated at the top of his class to receive
his M. Sc. in Chemistry from the Indian Institute of Technology.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX
Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2007 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.co
|
